Squarex Pharmaceutical Corporation (SQRX)

Squarex Pharmaceutical was planning to go public, but the IPO was withdrawn on May 19, 2023.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -635,099
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About SQRX

Squarex Pharmaceutical is a late-clinical-stage pharmaceutical company developing a drug that is intended to improve immune function to reduce severity and incidence of infectious disease with an initial focus on oral herpes. Our drug SQX770 has completed a Phase 1 and a Phase 2 placebo-controlled clinical trial and showed a statistically significant effect in non-primary endpoints in both trials of delaying time to next herpes labialis or oral herpes (cold sore) outbreak and reducing the number of outbreaks of cold sores (herpes labialis) afte... [Read more]

Industry Health Care
Sector Pharmaceuticals
Founded 2012
Employees 1
Stock Exchange NASDAQ
Ticker Symbol SQRX
Full Company Profile

Financial Performance

Financial Statements


Squarex Pharmaceutical IPO Registration Document (S-1)

Squarex Pharmaceutical has filed to go public with an IPO on the NASDAQ.

1 year ago - SEC